Explore our Novel Drug Pipeline

Cells under a microscope with vibrant fluorescent colors of blue, pink, green, and purple against a black background.

About Quantum X Scientific

Quantum X Scientific is paving the way for innovative therapeutic solutions to incurable diseases. Our novel drug platform is the spine of our innovative drug solutions to cancers and immune diseases, retraining the body to self heal, while targeting only destructive cells unlike conventional therapies. Discover our research and novel drug pipeline for more information.

Whats HLADrvax?

At Quantum X, we are redefining the future of autoimmune care with HLADrvax—a novel therapeutic solution designed to both treat early-stage Rheumatoid Arthritis (RA) and potentially prevent its onset.

Currently undergoing PHASE 2 Testing, HLADrvax leverages advanced biochemical and biological methodologies to address a critical unmet need in immunosuppressive disease treatment. Our innovative approach targets immune system regulation at its core, offering hope for millions affected by RA.

With HLADrvax, Quantum X is committed to closing the gap in autoimmune therapeutics—driving progress, promoting prevention, and improving lives. HLADrvax has surpassed successful preclinical trials- paving way for successful treatment approaches to deadly disease.

Close-up microscopic view of a plant stem cross-section showing cells with purple and pink stain, including vascular tissue and multiple layers of cells.

Innovative Therapeutics, Breakthrough Treatments

Innovative Therapeutics, Breakthrough Treatments

A series of black and white medical brain scan images, likely CT scans, arranged in a grid pattern with five rows and six columns.

NeuroVax-MS™ is a precision immunotherapy for multiple sclerosis that aims to selectively recalibrate pathogenic immune responses while preserving protective immunity. It is built on a proprietary platform that enables specific modulation of autoreactive pathways implicated in demyelination.

LupraMod™ is a novel therapy addressing the complexity of lupus by rebalancing immune hyperactivity and restoring tolerance mechanisms. Unlike broad immunosuppressants, LupraMod™ offers a more targeted approach to reduce flares and organ damage while minimizing infection risk.
:

Treatment of a Broad Spectrum of Cancers


We present the design and preclinical validation of OncoVax-p53. Leveraging the nanoparticle delivery expertise of the HLADRvax™ platform. OncoVax-p53 represents a scalable, broadly applicable immunotherapeutic strategy with the potential to benefit millions of cancer patients annually across a wide range of tumor types.


A molecular model made of colored sticks and balls representing atoms on a black background.

MetaboVax™ is a novel therapeutic designed to address obesity at its biological root by modulating appetite and energy regulation pathways. Its unique mechanism aims to provide durable weight management without the cardiovascular and gastrointestinal safety concerns of current agents.